A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2015
At a glance
- Drugs CNF 2024 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Biogen
- 09 Jun 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 20 May 2009 Additional lead trial investigator as Chris Storgard identified as reported by ClinicalTrials.gov.
- 20 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.